The European Commission granted an approval under exceptional circumstances to InflaRx’s immunosuppressant. The European ...

The risk of developing RDS was significantly increased among newborns born to mothers with confirmed COVID-19 infection during pregnancy.

InflaRx N.V. IFRX shares gained 7.7% on Wednesday following the European Commission's (EC) approval of marketing ...

InflaRx receives European marketing authorization for Gohibicto treat of SARS-CoV-2-induced acute respiratory distress syndrome: Jena, Germany Friday, January 17, 2025, 11:00 Hrs ...

The following is a summary of “Prognostic role of cardiac and inflammatory biomarkers in extubation failure in patients with COVID-19 acute respiratory distress syndrome,” published in the January ...

InflaRx (IFRX) announced that the European Commission has granted marketing authorization under exceptional circumstances for Gohibic for the ...

InflaRx (IFRX) has received EU regulatory approval for its treatment Gohibic for the treatment of COVID-19 patients ...

Study finds cardiovascular events in pregnancy significantly increase risks for preterm birth and SGA infants in autoimmune ...

H.C. Wainwright reaffirmed its Buy rating and $8.00 price target for InflaRx NV (NASDAQ:IFRX), following the European ...

Leerink Partners analyst Joseph Schwartz has maintained their bullish stance on IFRX stock, giving a Buy rating yesterday.Stay Ahead of the ...

June 10, 2024 — Scientists have grown 'mini-guts' in the lab to help understand Crohn's disease, showing that 'switches' that modify DNA in gut cells play an ... Major Cause of Inflammatory ...